SECsense Logo

AstraZeneca PLC May 2025 Form 6-K: CEO Pascal Soriot Takes New Director Role

$AZN
Form 6-K
Filed on: 2025-05-21
Source
AstraZeneca PLC May 2025 Form 6-K: CEO Pascal Soriot Takes New Director Role

Here are the key insights extracted from the provided financial report (Form 6-K) for AstraZeneca PLC:

  1. Filing Details:
  • Type: Form 6-K
  • Commission File Number: 001-11960
  • Reporting Period: Month of May 2025
  1. Company Information:
  • Company Name: AstraZeneca PLC
  • Headquarters Address:
    • 1 Francis Crick Avenue
    • Cambridge Biomedical Campus
    • Cambridge CB2 0AA
    • United Kingdom
  1. Director Declaration:
  • New Appointment: Pascal Soriot, the Chief Executive Officer (CEO) of AstraZeneca, has been appointed as a director of Agilent Technologies Inc.
  • Effective Date of Appointment: 21 May 2025.
  1. Regulatory Compliance:
  • The announcement was made in accordance with Listing Rule 6.4.9 (2).
  1. Company Overview:
  • AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines, particularly in the areas of Oncology, Rare Diseases, and BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology).
  • The company's medicines are sold in more than 125 countries.
  1. Contact Information:
  • For investor relations and media inquiries, specific contact links are provided (though not detailed in the text).
  1. Signatories:
  • The document is signed by Adrian Kemp, the Company Secretary of AstraZeneca PLC, on 21 May 2025.

This information highlights a significant leadership change within AstraZeneca, which may affect its strategic direction and relationships in the biopharmaceutical industry. The filing also confirms the company's adherence to regulatory requirements regarding disclosures of director appointments.